1. Indications and Usage
\nLocally Advanced or Metastatic Nasopharyngeal Carcinoma (NPC):
\nBecotatug Vedotin is indicated for the treatment of adult patients with locally advanced or metastatic nasopharyngeal carcinoma who have received prior platinum-based chemotherapy and PD-1 inhibitor therapy.
\n2. Dosage and Administration
\nRecommended Dosage:
\nStandard Dose: 2.2 mg\/kg administered as an intravenous infusion every 3 weeks.
\nDose Reduction: For patients who have experienced unacceptable toxicity, doses can be reduced to 1.8 mg\/kg and then to 1.4 mg\/kg.
\nAdministration Instructions:
\nInfuse through an intravenous line with a 0.2 micron or 0.22 micron inline filter.
\nDo not administer as an intravenous push or bolus.
\nDo not mix or co-administer with other drugs in the same infusion line.
\n3. Mechanism of Action
\nAntibody-Drug Conjugate (ADC):
\nBecotatug Vedotin is an anti-CD166 antibody conjugated to monomethyl auristatin E (MMAE).
\nPhysiological Effect:
\nBecotatug Vedotin binds to CD166 (Activated Leukocyte Cell Adhesion Molecule), which is overexpressed on tumor cells. The ADC is internalized and MMAE is released intracellularly.
\n4. Safety and Warnings
\nPeripheral Neuropathy:
\nPeripheral neuropathy may occur. Monitor patients for signs of neuropathy (numbness, tingling, or pain in the hands or feet). Dose delays or reductions may be required.
\nInfusion-Related Reactions:
\nMonitor patients during infusions. Interrupt or slow the rate of administration if severe reactions occur.
\nReproductive Toxicity:
\nMay cause fetal harm. Advise females of reproductive potential to use effective contraception during treatment and for at least 3 months after the final dose.
\n5. Adverse Reactions
\nMost Common:
\nPeripheral neuropathy, anemia, fatigue, nausea, vomiting, alopecia, and rash.
\n6. Drug Interactions
\nNo Specific Interactions:
\nNo formal drug interaction studies have been conducted.
\n7. Pharmaceutical Information
\nStorage:
\nStore at 2\u00b0C to 8\u00b0C (36\u00b0F to 46\u00b0F) in the original carton to protect from light. Do not shake.<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name: \u7f8e\u4f51\u6052 \u00ae(Meiyouheng\u00ae)
\nGeneric Name: Becotatug Vedotin
\nStrength: 50 mg per vial, 1 vial per box
\nManufacturer: Dongyao Pharmaceutical Co., LTD. (Entrusted production)
\nMarketing Authorization Holder: Lepu Biological Technology Co., LTD
\nApproval Date in China: October 30, 2025
\nRegistration Number: \u56fd\u836f\u51c6\u5b57 S20250057
\nStorage: Store and transport at 2\uff5e8\u2103, protected from light; keep away from children.<\/p>\n
Price&Cost:Contact Us now for the best price of Becotatug Vedotin(Meiyouheng\uff09<\/p>\n","protected":false},"featured_media":3234,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[25,73],"product_tag":[],"class_list":["post-3232","product","type-product","status-publish","has-post-thumbnail","product_cat-injection","product_cat-chinese-innovative-drug","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n